CD40 and Patent ductus arteriosus: Recently, a phase I clinical trial using a combination of a CD40 agonist and standard-of-care chemotherapy (nab-paclitaxel + gemcitabine), with or without anti–programmed cell death 1 (αPD-1) elicited clinical responses in a subset of evaluable patients with metastatic PDA, suggesting that immune-based treatments can target advanced disease (6).